The observed increase in CCT2 expression in advanced AMD may coincides with the limited efficacy of autophagy-targeting therapeutic strategies (such as mTOR inhibition, a major negative regulator of autophagy initiation) in clinical trials for advanced AMD29,30. Here, CCT2 is linked to age-related macular degeneration.